The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial.

Eric Lawitz, Mohamed Bidair,Thomas Marbury,Christopher T Jones,Avantika Barve,Baldur Magnusson,David T Barkan,Ursula Bodendorf,Kathryn Bracken, Erica Canino,Darlene Chen,Kristina Dabovic,Tycho Heimbach, Marjorie Ison,Catherine L Jones,Steven J Kovacs,Jay P Lakshman,Bin Li,Prakash Raman, Rachael Steiner-Swiat,Sanjeev Thohan,Kelly A Wong,Weidong Zhong,Richard A Colvin

Clinical Therapeutics（2018）

引用 0|浏览24

暂无评分

摘要

Coadministration of ritonavir with BZF961 boosted BZF961 exposure (including C, which is the clinically relevant parameter associated with antiviral activity) in a therapeutic range with less variability compared with BZF961 alone. For strategic reasons, BZF961 is no longer under development.

查看译文

关键词

clinical trial,hepatitis C,protease inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要